CorMedix (CRMD) presents a potential buying opportunity as the stock appears undervalued despite strong Q3 earnings and rapid growth of its DefenCath product. The company is profitable, has no debt, and trades at a low forward valuation of just 3.5 times its projected 2025 adjusted EBITDA. The recent acquisition of Melinta Therapeutics strengthens its position as a specialized anti-infection company with expected cost savings of over $30 million. While a key risk is the CMS reimbursement negotiation for DefenCath in January, this concern may already be priced into the stock. The disconnect between CRMD's strong fundamentals and its current share price could represent an attractive entry point for long-term investors.

CorMedix (CRMD)

• The podcast host presents a bullish case for CorMedix (CRMD), highlighting that the company delivered an "outstanding" Q3 earnings report but saw its stock price fall due to negative broader market sentiment against growth stocks.

• The host believes the stock is being "unfairly punished" by the market, which is focused on macro issues like a potential government shutdown rather than company-specific fundamentals.

• Q3 Financial Performance:

  • DefenCath sales showed huge growth, increasing from $39 million to $88.8 million quarter-over-quarter. This was driven by higher-than-expected utilization from a large dialysis customer (either DaVita or Fresenius).
  • The company raised its full-year revenue guidance to $390 - $400 million.
  • Reported a strong Q3 net income of $108 million, or $1.26 - $1.42 per share.
  • The company has no debt and $56 million in cash.

• Valuation:

  • The host describes the stock as "dirt cheap".
  • The company's Enterprise Value is $820 million.
  • Projected 2025 Proforma Adjusted EBITDA is $230 million.
  • This results in a very low forward valuation multiple of 3.5x Enterprise Value / Adjusted EBITDA.

• Product & Market:

  • CorMedix's main product is DefenCath, a solution used to "lock" hemodialysis catheters after treatment.
  • Its primary function is to prevent catheter-related infections, which are costly and dangerous.
  • Using DefenCath reduces infection-related deaths by 71% and saves Medicare an estimated $70,000 - $80,000 per avoided hospitalization.

• Melinta Therapeutics Acquisition:

  • CorMedix acquired Melinta Therapeutics, a company with a portfolio of anti-infection drugs.
  • The host views this acquisition positively, as it creates synergies and strengthens CorMedix's focus on becoming a specialized "anti-infection therapeutics company."
  • Expected cost savings are $30 million quickly, growing to $35 - $45 million by the end of 2025.

• Risks Mentioned:

  • A key risk is the upcoming reimbursement rate renegotiation with CMS (Centers for Medicare & Medicaid Services) in January.
  • The price per vial, currently over $200, could potentially be lowered to the $120 - $130 range.
  • However, the host believes this risk is already "more than priced into the stock" and that the company's rapid growth could absorb such a price reduction.

• Future Growth (Optionality):

  • The company is working on applying DefenCath for use with TPN (Total Parenteral Nutrition) catheters, which are feeding tubes used for hospital patients.
  • Success in this area could "greatly increase the market size" for the product.

Takeaways

• Investment Thesis: The podcast suggests that CorMedix is a fundamentally strong, fast-growing, and profitable company trading at a very low valuation. The current stock price appears disconnected from its positive business performance, presenting a potential opportunity for long-term investors.
• Bullish Case: Investors who believe in the company's product, growth trajectory, and management's strategy could see the current price as an attractive entry point. The company is generating significant cash flow and has a clear path to cost savings and market expansion.
• Key Risk to Watch: The primary near-term risk is the outcome of the CMS reimbursement negotiation in January. A significant price reduction for DefenCath could negatively impact future revenue and profitability, even if the host believes this is already priced in.
• Investor Profile: This opportunity may be suitable for investors with a long-term horizon who can tolerate short-term volatility and are willing to invest in a small-cap healthcare stock that is currently out of favor with the broader market.